The Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial randomized 2368 patients with type 2 diabetes (T2DM) and coronary artery disease to either prompt revascularization or intensive medical therapy alone; and to either insulin-sensitization or insulin-provision diabetes therapy. Randomization was stratified by proposed revascularization method. Five-year survival and major cardiovascular events (MACE) were similar in study subgroups except in the coronary bypass surgery (CABG) stratum where there were fewer MACE after revascularization. There was less hypoglycaemia and weight gain, and greater apparent benefit from CABG in the insulin sensitization group. BARI 2D has provided important data for clinicians.
BARI 2D aimed to answer two important clinical questions in patients with diabetes and angiographic CAD whose background medical therapy was actively managed to provide contemporary secondary CV protection. First, does a strategy of prompt or initial revascularisation offer benefits over medical therapy combined with delayed or no revascularisation? And second, does a strategy of insulin providing diabetes therapy offer CV benefits over a strategy of insulin sensitisation? BARI 2D was therefore a trial that compared strategies of management of myocardial ischaemia and glycaemia and was not a test of PCI versus coronary artery bypass graft (CABG) surgery, or a test of individual diabetes drugs or of HbA 1C targets.
Why is the BARI 2D study important?
Death from heart disease is two to four times higher in patients with diabetes compared with the general population and more than two thirds of patients with type 2 diabetes (T2DM) die from cardiovascular disease (CVD). There are compelling reasons why The Bypass Angioplasty Revascularisation Investigation 2 Diabetes (BARI 2D) 1 is an important trial.
First, the value of revascularisation has been shown to reduce death and myocardial infarction in high-risk patients, but results have been inconsistent in patients with less severe disease. [2] [3] [4] For example, the COURAGE trial showed that in patients with stable coronary artery disease (CAD), initial management by angioplasty (PCI) did not reduce the risk of death or major cardiovascular (CV) events when added to optimal medical therapy. 2 Moreover, these studies did not focus on patients with diabetes, in whom symptoms are a less reliable indicator of the CAD severity.
Second, in patients with T2DM, insulin therapy and/or insulin levels as well as insulin resistance have been associated with adverse CV outcomes. Treatment for T2DM can be divided into agents that are insulin providing (insulin and sulphonylureas) or agents that could be considered insulin sensitising (metformin and thiazolidinediones). At the time BARI 2D was designed, it was not clear whether one type of diabetes treatment could yield better CV outcomes.
How did BARI 2D address these two questions?
The study enrolled patients with T2DM and documented myocardial ischaemia who had least one significant coronary stenosis at angiography. Recruitment was from the United States (two thirds of the patients), Canada, Brazil, Mexico and Europe, and of the 2,368 randomised patients (mean age 62 years, 30% female), one third were from an ethnic/racial minority background and one third had a history of prior myocardial infarction. Half of the patients had stable angina, 10% had unstable angina, and 18% had no angina or anginal equivalents. Exclusion criteria included renal failure (creatinine > 177 μmol/L), heart failure and coronary revascularisation within 12 months of randomisation.
Much is known about the CV benefits of optimal management of diabetes and CV risk factors in patients with T2DM, 5 and it was therefore important that the study be performed in the setting of treatment for guideline-driven targets for LDL-cholesterol, blood pressure and aspirin use.
How were the patients selected and randomised?
Prior to the patient being considered for randomisation, the local cardiologist determined that the patient could be managed either by medical therapy or by revascularisation. This meant that patients were excluded if they had severe angina or severe coronary disease such as left main disease that mandated prompt revascularisation; and patients were excluded if they had mild disease that was more suitable for medical therapy.
The trial had a 2 × 2 factorial design ( Figure 1 ). Once consented and after review of the coronary angiogram, the cardiologist selected the most appropriate revascularisation method: either PCI or CABG, based on clinical and angiographic factors. Patients in each stratum were then randomised to the intended revascularisation method versus medical therapy for CAD. Patients with single-or two-vessel disease (two thirds of the patients) tended to beallocated to PCI and those with more severe triple vessel disease (one third of the patients) were more often allocated to CABG.
A second randomisation allocated patients to receive insulin providing (sulphonylurea and/or insulin) or insulin sensitising therapies (metformin, and/or a thiazolidinedione (TZD) (usually rosiglitazone)), with a target HbA 1C of ≤ 7.0% in both groups.
The principal and main secondary endpoints were all cause mortality and major CV events (death, non-fatal myocardial infarction or stroke) over 5.3 years of follow-up.
It is important to note that all patients received intensive medical therapy with the aim of achieving uniform management of glycaemia (target HbA 1C < 7.0%), lipids (LDL-cholesterol target < 2.6 mmol/L), blood pressure (target ≤ 130/80 mmHg), angina and lifestyle factors in all groups.
What were the main results?
The study demonstrated similar mortality rates and CV event rates in groups allocated to prompt revascularisation versus medical therapy (survival: 88% vs. 88%, p=0.97; freedom from CVD event: 77% vs. 76%, p=0.70); and similar outcomes in groups receiving insulin sensitisation versus insulin providing therapies (survival: 88% vs. 88%, p=0.89; freedom from CVD event: 78% vs. 75%, p=0.13).
The study showed that among high-risk patients selected for CABG, prompt revascularisation reduced major CV events compared with medical therapy (22% vs. 31%, p=0.01), whereas in lower-risk patients selected for PCI there was no benefit associated with prompt revascularisation. In the CABG stratum, non-fatal myocardial infarction occurred much less frequently in those who were treated with revascularisation (7%) than in the medical-therapy group (15%).
Although other outcomes should be viewed with caution there were some interesting and potentially important observations. First, compared with insulin providing therapy, a strategy of insulin sensitisation was associated with less weight gain (0.3 vs. 2.1 kg), lower waist circumference (2 cm difference), higher HDL-cholesterol, lower HbA 1C , (0.5% difference), and less hypoglycaemia (see below) at 3 years. Second, the effect of revascularisation on the rate of CV events was particularly evident among patients in the CABG stratum who were assigned to the insulin sensitising strategy, with an CV event rate of 19% in patients treated by revascularisation compared with 32% in medicallytreated patients (p=0.002).
The reason why insulin sensitising therapy was associated with better outcomes in the CABG stratum who underwent revascularisation is unclear but based on ACCORD, ADVANCE and VADT 6 it is unlikely to be explained by the relatively small difference in HbA 1C observed (< 0.5%) between insulin sensitising and providing therapy strata. 
What about adverse events?
Episodes of hypoglycaemia were commonly reported in both diabetes therapy groups but predictably were more common in patients assigned to an insulin providing strategy (any hypoglycaemia: insulin providing vs. sensitisation: 74% vs. 53%; severe hypoglycaemia, 9.1% vs. 5.9%; both p<0.004).
Insulin sensitisation therapy as associated with a slightly higher rate of peripheral oedema (57% vs. 52%, p=0.02) but rates of heart failure were similar in insulin sensitisation (19%) and insulin providing groups (17%), p=0.09.
What are the main strengths of the trial?
The trial addressed important clinical questions and the randomisation strategies were generally very effective. BARI 2D patients met 'uncertain' or 'appropriate' criteria for revascularisation by current guidelines, 7 and baseline use of diabetes medication was similar to general use in the USA. The study was conducted in the setting of lifestyle advice and aggressive CVD risk factor management in all patients (medication use: statin (95%), aspirin (94%), beta blocker (~86%) and ACE-inhibitor or ARB therapy (~91%)). At 3 years 83% of patients achieved an LDLcholesterol < 2.6 mmol/L, 71% achieved a blood pressure of ≤ 130/80 mmHg and 89% were not smoking.
What are the limitations?
The study selection criteria limit the generalisability of the results to all patients with T2DM and CAD because many patients with very mild disease and severe symptoms or disease were not enrolled. Overall, BARI 2D patients were at relatively low CVD risk.
The study was underpowered to detect between-group mortality differences of < 3% and < 6% for major CV events.
There was some cross-over in the glucose management arms, for example more than one third of the patients randomised to an initial insulin sensitising strategy were receiving an insulin providing therapy at 1 year because of failure to maintain HbA 1C < 8/0%, and this figure had risen to more than a half by 5 years. Similarly, ~2 in every 5 patients randomised to initial medical therapy had received revascularisation by 5 years because of progression of angina, acute coronary syndrome or severe ischaemia.
Drug eluting stents became available half way through the 5-year recruitment period (April 2003) and this meant that only one third of PCI stratum patients who received revascularisation were treated with these devices. Their low rates of use in BARI2 2D probably did not affect the results because they have not been shown to reduce rates of death or major CV events. 8
How do the results compare with other studies?
BARI 2D results on PCI are consistent with those from COURAGE, in which the majority of patients did not have diabetes. 2 A sub-group analysis of BARI 2D will examine the effect of PCI on the prevalence of angina.
Although BARI 2D compared two diabetes treatment strategies, and it did not assess the effect of a specific drug, no safety concerns were seen for the insulin providing strategy, in which over 60% of patients were using TZDs, predominantly rosiglitazone. These results are therefore consistent with the results of RECORD. 9
Should the results influence my clinical practice?
The study was designed to help physicians make treatment decisions and it has important clinical implications for patients with T2DM and stable CAD with documented myocardial ischaemia.
First, patients with extensive multi-vessel CAD should be considered for early CABG; and second, those patients with less extensive CAD can be managed equally safely with intensive medical therapy until revascularisation becomes clinically indicated because of symptoms.
Overall both insulin sensitising and insulin providing approaches appeared appropriate for BARI 2D eligible patients. However, there were some important benefits of an insulin sensitisation strategy (lower weight, waist circumference and HbA 1C and less hypoglycaemia) especially in patients being considered for CABG in whom there was a borderline (p=0.06) benefit on CVD events. Therefore an insulin sensitising strategy could be considered in patients undergoing revascularisation who need improved glycaemic control.
What are the take home messages?
BARI 2D showed that in patients with T2DM and stable CAD with documented ischaemia, mortality was not influenced by prompt revascularisation or by diabetes management strategies that adopted insulin provision or sensitisation.
In appropriately chosen T2DM patients CABG was superior to medical therapy alone in reducing CV events, particularly among patients assigned to receive insulin sensitisation.
Therapeutic decisions regarding management of CAD and glycaemia in T2DM should continue to be made jointly by the patient's cardiologist, diabetologist and primary care physician.
